Clay Siegall, who has 20 years of experience in the field of cancer research and pharmaceutical drug development, co-founded a company called Seattle Genetics in 1998 that is involved with using biotechnology to create anti-body based treatments for many types of cancer. The company developed an FDA-approved drug called Adcetris, which is also known as brentuximab vedotin, and it is used for providing therapy to patients who suffer from diseases like Hodgkin’s lymphoma, a condition where cells grow rapidly and have the potential to spread to different areas of the body.
Before becoming one of the founding members of Seattle Genetics, Clay Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator, a position he held from 1991 to 1995. He graduated from George Washington University with a PhD in Genetics, and from the University of Maryland with a BS degree in Zoology. He is the owner of 15 patents, and the author of nearly 70 papers based on scientific research. He also serves on the Board of Directors at a private biotechnology organization named Alder BioPharmaceuticals.
He became the President of Seattle Genetics in June of the year 2000, and its Chief Executive Officer in November of 2002. Aside from serving in those top positions, he writes a blog where he covers a variety of topics involving scientific research and accomplishments, an area he has a great deal of interest in, and one where he’s always seeking out new developments to inform readers about. He has a passion for helping patients get better treatment for their diseases, and with his company’s drug, Adcetris, which has now been approved in more than 65 countries, including Canada, he is helping to improve the lives of many cancer victims.
Clay Siegall is the recipient of several business awards, and he got the idea to start his company after he witnessed his father struggle with the progression of the cancer he’d been stricken with years ago. Seeing that there were limited ways to fight the disease at that time, he felt that he needed to assist oncologists in coming up with a more effective cancer therapy method.